Physicians and scientists from the UCLA Jonsson Complete Most cancers Heart will talk about the newest analysis and scientific trial outcomes on mixture therapies for breast most cancers, a possible new therapy for sufferers with recurrent glioma, and advances in PSMA PET guided radiotherapy for sufferers with prostate most cancers, amongst different matters, on the American Society of Medical Oncology’s annual assembly.
At this yr’s scientific discussion board, Dr. Dennis Slamon, chair of hematology-oncology and director of scientific and translational analysis on the UCLA Jonsson Complete Most cancers Heart, will current findings from the NATALEE scientific trial (summary LBA500), which seems at including ribociclib, a focused remedy drug, to straightforward hormone remedy as adjuvant therapy for sufferers with early hormone-receptor constructive/HER2 adverse breast most cancers. The outcomes will likely be highlighted through the oral presentation on June 2 at 2:45pm CT in Corridor D1.
Dr. Timothy Cloughesy, professor of neuro-oncology on the David Geffen Faculty of Drugs at UCLA, is the senior creator of summary LBA1, which highlights INDIGO scientific trial outcomes, a world, randomized double-blinded, part 3 examine of vorasidenib verse placebo in sufferers with residual or recurrent grade 2 glioma with an IDH1/2 mutation. The findings will likely be introduced through the plenary session on June 4 at 1PM CT in Corridor B1.
On this time of exceptional and speedy development in most cancers medication, the info and experiences introduced throughout these periods at ASCO provide necessary insights into rising areas of examine, and permit a vital open discussion board for participation with a variety of high specialists.”
Dr. Michael Teitell, Director, UCLA Jonsson Complete Most cancers Heart
Highlights of noteworthy displays at ASCO 2023 that function contributions from UCLA researchers embody (all instances are listed in CDT):
Breast most cancers
Oral summary session
Part III NATALEE trial of ribociclib + endocrine remedy as adjuvant therapy in sufferers with HR+/HER2− early breast most cancers.
Summary: LBA500
Presenter: Dennis Slamon, MD, PhD
Date: June 2 at 2:45PM
Location: Corridor D1
Poster periods
A part 3 examine of gedatolisib plus fulvestrant with and with out palbociclib in sufferers with HR+/ HER2- superior breast most cancers beforehand handled with a CDK4/6 inhibitor plus a nonsteroidal aromatase inhibitor (VIKTORIA-1).
Summary: TPS1118 | Poster Bd #: 335b
Presenter: Sara A. Hurvitz, MD, FACP
Date: June 4 from 8 to 11AM.
Location: Corridor A
UCLA B-13: A part 1b trial evaluating the protection of ribociclib, tucatinib, and trastuzumab in sufferers with metastatic, HER2+ breast most cancers and a multicenter, randomized, open-label, part 2 examine of preoperative therapy with ribociclib, trastuzumab, tucatinib, with or with out fulvestrant versus docetaxel, carboplatin, trastuzumab, and pertuzumab in HR+/HR-, HER2+ breast most cancers.
Summary: TPS1116 | Poster Bd #: 334b
Presenter: Nicholas Patrick McAndrew, MD, MSCE
Date: June 4 from 8 to 11AM.
Location: Corridor A
A part 1, first-in-human, open label, escalation and enlargement examine of ORM-5029, a extremely potent GSPT1 degrader focusing on HER2, in sufferers with HER2-expressing superior stable tumors.
Summary: TPS1114 | Poster Bd #: 333b
Presenter: Sara A. Hurvitz MD, FACP
Date: June 4 from 8 to 11AM.
Location: Corridor A
Mind tumors
Plenary session
INDIGO: A world, randomized, double-blinded, part 3 examine of vorasidenib versus placebo in sufferers with residual or recurrent grade 2 glioma with an IDH1/2 mutation.
Summary: LBA1
Senior Creator: Timothy Cloughesy, MD
Date: June 4 at 1PM
Location: Corridor B1.
Poster session
Depth of radiographic response (DpR) and time to tumor regrowth (TTG) to foretell general survival following anti-VEGF remedy in recurrent glioblastoma.
Summary: 2063 | Poster Bd #: 420
Presenter: Benjamin M. Ellingson, PhD
Date: June 3 from 1:15 to 4:15PM
Location: Corridor A
Prostate most cancers
Poster dialogue periods
PSMA PET guided salvage radiotherapy amongst sufferers with prostate most cancers within the post-prostatectomy setting: A single heart post-hoc evaluation.
Summary: 5009 | Poster Bd #: 103
Presenter: Jeremie Calais, MD, MSc
Date: June 3 from 1:15 to 2:45PM
Location: E450
Do bone scans over-stage illness in comparison with PSMA PET? A global multicenter retrospective examine with blinded impartial readers.
Summary: 5011 | Poster Bd #: 105
Presenter: Wolfgang Peter Fendler, MD
Date: June 3 from 1:15 to 2:45PM
Location: E40
Poster periods
Early findings from the GARUDA trial: The affect of a genetic signature of late radiation toxicity on prostate most cancers therapy resolution making.
Summary: 5089 | Poster Bd #: 183
Presenter: Joanne B. Weidhaas, MD, PhD
Date: June 3 from 8 to 11AM
Location: Corridor A
PSMA PET findings in an “EMBARK-like” cohort of sufferers with high-risk non-metastatic hormone-sensitive prostate most cancers: A single heart post-hoc retrospective evaluation.
Summary: 5091 | Poster Bd #: 185
Presenter: Wesley Robert Armstrong, BS
Date: June 3 from 8 to 11AM
Location: Corridor A
Genomic alterations and self-reported Agent Orange publicity in United States veterans with metastatic prostate most cancers.
Summary: 5068 | Poster Bd #: 162
Presenter: JJ Haijing Zhang, MD
Date: June 3 from 8 to 11AM
Location: Corridor A
Blood most cancers
Poster session
UCHMC 1812: A part 1b trial of CPX-351 plus gemtuzumab ozogamicin for relapsed/refractory acute myeloid leukemia.
Summary: 7024 | Poster Bd #: 154
Presenter: Sunmin Park, MD, PhD
Date: June 5 from 8 to 11AM
Location: Corridor A
Colorectal most cancers
Poster session
STELLAR-303: A part 3 examine of XL092 together with atezolizumab versus regorafenib in sufferers with beforehand handled metastatic colorectal most cancers.
Summary: TPS3630 | Poster Bd #: 327a
Presenter: J. Randolph Hecht, MD
Date: June 5 from 8 to 11AM
Location: Corridor A
Kidney most cancers
Poster session
Zr-DFO-girentuximab for PET/CT imaging of clear cell renal cell carcinoma: Outcomes from part 3 ZIRCON examine.
Summary: 4554 | Poster Bd #: 46
Presenter: Brian M. Shuch, MD
Date: June 3 from 8 to 11AM
Location: Corridor A
Ovarian most cancers
Poster session
Preliminary outcomes of dose discovering in a first-in-human part 1 examine of a novel Claudin 6 (CLDN6) focused antibody drug conjugate (ADC) TORL-1-23 in sufferers with superior stable tumors.
Summary: 3082 | Poster Bd #: 280
Presenter: Gottfried E. Konecny, MD
Date: June 3 from 8 to 11AM
Location: Corridor A
